HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women

Sexually Transmitted Infections

Volumn 90, Issue 5, 2014, Pages 363-369

  Guffey, M Bradford ^a,b   Richardson, Barbra ^c,d   Husnik, Marla ^c   Makanani, Bonus ^e   Chilongozi, David ^f   Yu, Elmer ^g   Ramjee, Gita ^h   Mgodi, Nyaradzo ⁱ   Gomez, Kailazarid ^j   Hillier, Sharon L ^k   Karim, Salim Abdool ^l  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MALAWI   (Malawi)

^f UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁱ UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^j FAMILY HEALTH INTERNATIONAL   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

^l UNIVERSITY OF KWAZULU NATAL   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPOL 974P; PLACEBO; PRO 2000;

ADULT; ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; COUNSELING; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; GONORRHEA; HUMAN; INCIDENCE; INFECTION PREVENTION; LABORATORY TEST; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE; TRICHOMONIASIS; VAGINA SMEAR;

CHLAMYDIA TRACHOMATIS; MICROBICIDES; NEISSERIA GONORRHOEA; PREVENTION; TRICHOMONAS;

ACRYLIC RESINS; ADMINISTRATION, TOPICAL; ADULT; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CONDOMS; DIRECTIVE COUNSELING; FEMALE; GONORRHEA; HEALTH PROMOTION; HIV INFECTIONS; HUMANS; MALAWI; NAPHTHALENESULFONATES; POLYMERS; RISK REDUCTION BEHAVIOR; SEXUAL BEHAVIOR; SOUTH AFRICA; TREATMENT OUTCOME; TRICHOMONAS VAGINITIS; UNITED STATES; VAGINA; ZAMBIA; ZIMBABWE;

EID: 84904605527     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051537     Document Type: Article

References (31)

1. World Health Organization. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015. Geneva, 2007.
2. Pinkerton SD, Layde PM. Using sexually transmitted disease incidence as a surrogate marker for HIV incidence in prevention trials: a modeling study. Sex Transm Dis 2002;29:298-307. (Pubitemid 34477920)
3. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17. (Pubitemid 29117474)
4. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163:233-9.
5. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102. (Pubitemid 23069039)
6. UNAIDS. Joint United Nations Programme on HIV/AIDS. 2008 Report on the global AIDS Epidemic. http://data.unaids.org/pub/GlobalReport/2008/
7. Rohan LC, Hillier SL, Dezzutti CS. Preventing the sexual transmission of HIV-1 with topical microbicides: another piece of the equation. J Infect Dis 2007;196:1285-7. (Pubitemid 351411999)
8. Vickerman P, Foss A, Watts C. Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. J Acquir Immune Defic Syndr 2008;48:460-7.
9. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329-37.
10. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25:957-66.
11. Amaral E, Faundes A, Zaneveld L, et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 1999;60:361-6. (Pubitemid 30133226)
12. Mahmoud EA, Svensson LO, Olsson SE, et al. Antichlamydial activity of vaginal secretion. Am J Obstet Gynecol 1995;172(4 Pt 1):1268-72.
13. Spencer SE, Valentin-Bon IE, Whaley K, et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis 2004;189:410-19. (Pubitemid 38210577)
14. Achilles SL, Shete PB, Whaley KJ, et al. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis 2002;29:655-64. (Pubitemid 35266407)
15. Zeitlin L, Hoen TE, Achilles SL, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001;28:417-23. (Pubitemid 32613686)
16. Patton DL, Sweeney YC, Cummings PK, et al. Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 2004;31:290-6. (Pubitemid 38542658)
17. Profy AT, Sonderfan AJ, Chancellor T, et al. PRO 2000: a candidate topical microbicide based on naphthalene sulfonate polymer with antimicrobial and contraceptive properties. Abstract B20; Microbicides 2000; Washinton, DC, 2000.
18. Profy AT, Sonderfan AJ, Bernstein DI, et al. PRO 2000 gel, a potential topical microbicide for HIV prevention, can block infection by other sexually transmitted disease pathogens. Abstract Number 33146; International Conference on AIDS; Geneva, Switzerland, 1998.
19. World Health Organization. Guidelines for the management of sexually transmitted infections. 2001. http://www.who.int/hiv/pub/sti/en/ STIGuidelines2003.pdf (accessed 29 May 2014).
20. Pattullo L, Griffeth S, Ding L, et al. Stepwise diagnosis of Trichomonas vaginalis infection in adolescent women. J Clin Microbiol 2009;47:59-63.
21. Cook RL, Hutchison SL, Ostergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005;142:914-25. (Pubitemid 40791807)
22. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004;190:666-74. (Pubitemid 39049994)
23. Richardson BA, Kelly C, Ramjee G, et al. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr 2013;63:120-5.
24. Stukel TA, Glynn RJ, Fisher ES, et al. Standardized rates of recurrent outcomes. Stat Med 1994;13:1781-91. (Pubitemid 24284860)
25. Kapiga S, Kelly C, Weiss S, et al. Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis 2009;36:199-206.
26. Richardson BA, Kelly C, Ramjee G, et al. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr 63:120-5.
27. Mayaud P, Mabey D. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect 2004;80:174-82. (Pubitemid 38746191)
28. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). Oral Abstract 26LB; 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, 2013.
29. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87.
30. van der Elst EM, Okuku HS, Nakamya P, et al. Is Audio Computer-Assisted Self-Interview (ACASI) Useful in Risk Behaviour Assessment of Female and Male Sex Workers, Mombasa, Kenya? PLoS ONE 2009;4:e5340.
31. Moodley P, Sturm AW. Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet 2005;366:1159.